Bodenheimer, T. High and rising health care costs. Part 2: Technologic innovation. Ann Intern Med. 2005;142:932–937.
Vallejo-Torres, L, Steuten, L, Parkinson, B, Girling, AJ, Buxton, MJ. Integrating health economics into the product development cycle: A case study of absorbable pins for treating hallux valgus. Med Decis Making. 2011;31:596–610.
Girling, A, Young, T, Brown, C, Lilford, R. Early-stage valuation of medical devices: The role of developmental uncertainty. Value Health. 2010;13:585–591.
Vallejo-Torres, L, Steuten, LM, Buxton, MJ, et al.
Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach. Int J Technol Access Health Care. 2008;24:459–464.
Cosh, E, Girling, A, Lilford, R, McAteer, H, Young, T. Investing in new medical technologies: A decision framework. J Commer Biotechnol. 2007;13:263–271.
Postmus, D, de Graaf, G, Hillege, HL, Steyerberg, EW, Buskens, E. A method for the early health technology assessment of novel biomarker measurement in primary prevention programs. Stat Med. 2012;31:2733–2744.
van de Wetering, G, Steuten, LM, von Birgelen, C, Adang, EM, IJzerman, MJ. Early Bayesian modeling of a potassium lab-on-a-chip for monitoring of heart failure patients at increased risk of hyperkalaemia. Technol Forecast Soc Change. 2012;79:1268–1279.
van Nimwegen, KJM, Schieving, JH, Willemsen, MA, et al.
The diagnostic pathway in complex paediatric neurology: A cost analysis. Eur J Paediatr Neurol. 2015;19:233–239.
Hoch, JS, Briggs, AH, Willan, AR. Something old, something new, something borrowed, something blue: A framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–430.
The use of health economics in the early evaluation of regenerative medicine therapies. PhD thesis. 2010.
McAteer, H, Cosh, E, Freeman, G, et al.
Cost‐effectiveness analysis at the development phase of a potential health technology: Examples based on tissue engineering of bladder and urethra. J Tissue Eng Regener Med. 2007;1:343–349.
Buchanan, J, Wordsworth, S, Schuh, A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14:1833–1847.
Regier, DA, Friedman, JM, Makela, N, Ryan, M, Marra, CA. Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: Willingness to pay from families of affected children. Clin Genet. 2009;75:514–521.
de Ligt, J, Willemsen, MH, van Bon, BWM, et al.
Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367:1921–1929.
Chapman, A, Taylor, C, Girling, A, editors. Early HTA to inform medical device development decisions-the headroom method. XIII Mediterranean Conference on Medical and Biological Engineering and Computing
2013. New York: Springer; 2014.
Girling, A, Lilford, R, Cole, A, Young, T. Headroom approach to device development: Current and future directions. Int J Technol Assess Health Care. 2015;31:331–338.
Lin, PJ, Cangelosi, MJ, Lee, DW, Neumann, PJ. Willingness to pay for diagnostic technologies: A review of the contingent valuation literature. Value Health. 2013;16:797–805.
Johnson, FR, Lancsar, E, Marshall, D, et al.
Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16:3–13.
Lancsar, E, Louviere, J. Conducting discrete choice experiments to inform healthcare decision making: A user's guide. Pharmacoeconomics. 2008;26:661–677.
Grosse, SD, Wordsworth, S, Payne, K. Economic methods for valuing the outcomes of genetic testing: Beyond cost-effectiveness analysis. Genet Med. 2008;10:648–654.
Guest, G, Namey, E. Public health research methods. Thousand Oaks, CA: SAGE Publications; 2014.